Neutralizing antibodies (nAbs) against SARS-CoV-2 represent a promising option for treating COVID-19. Screening a large and diverse antibody phage library has allowed for the rapid discovery of anti-SARS-CoV-2 nAbs.
In this expert webinar, find out how high-throughput epitope binning and mapping using label-free biolayer interferometry (BLI) detection and advanced flow cytometry systems has enabled the development of an antibody cocktail that can reduce the risk of drug resistance.
Download the webinar to learn more.
Please select your country so we can show you products that are available for you.
The content of our website is always available in English and partly in other languages. Choose your preferred language and we will show you the content in that language, if available.